Evaluate Long-Term Safety and Efficacy of Pregabalin in Patients With Chronic Neuropathic Pain.
NCT00141362
ABOUT THIS STUDY
FOR MORE INFORMATION
Contact a representative by phone, email, or visiting the study website. Please see the references below:
Pfizer Clinical Trials Contact Center
1-800-718-1021
- Must have met the inclusion criteria for the preceding double-blind BID study in diabetic neuropathy or postherpetic neuralgia.
- Must have received study medication under double-blind conditions.
- Patients cannot participate if they experienced a serious adverse event during the
previous double-blind BID study which was determined to be related to the study
medication.
NEED INFO?
Questions about a trial? Call or email to reach a Pfizer Clinical Trial Contact Center Representative
TRY A NEW SEARCH
Search for Clinical Trials by condition, keyword or trial number. Share your location or enter your city or zip code to find studies near you.
Based on your search, you may also be interested in
- Ottawa, Ontario
- Funabashi, Chiba
- Ichikawa, Chiba
- Matsudo, Chiba
- Sagamihara, Kanagawa
- Ageo, Saitama
- Saitama-shi, Saitama
- Edogawaku, Tokyo
- Kotoku, Tokyo
- Nerimaku, Tokyo
- Toshimaku, Tokyo
- Kofu, Yamanashi
- Port Macquarie, New South Wales
- Randwick, New South Wales
- Westmead, New South Wales
- Coopers Plain, Queensland
- Townsville, Queensland
- Heidelberg, Victoria
- Prahran, Victoria
- Perth, Western Australia
- Warrawong, New South Wales
- Westmead, New South Wales
- Kippa Ring, Queensland
- Maroochydore, Queensland
- Bedford Park, South Australia
- Perth, Western Australia
- Woodville,
- Kelowna, British Columbia
- Halifax, Nova Scotia
- Toronto, Ontario
- Sherbrooke, Quebec
- Ste-foy, Quebec
- Brno,
- Ceske Budejovice,
- CZ-Praha 8,
- Plzen,
- Praha 5,
- Arnhem,
- Breda,
- Kampen,
- Roosendaal,
- Rotterdam,
- Stadskanaal,
- Barcelona,
- Granada,
- Madrid,
- Malaga,
- Sevilla,
- Portsmouth, Hants
- Northampton, Northants
- London,
Descriptive Information | ||||
---|---|---|---|---|
Brief Title ICMJE | Evaluate Long-Term Safety and Efficacy of Pregabalin in Patients With Chronic Neuropathic Pain. | |||
Official Title ICMJE | An Open-Label, Extension Safety and Efficacy Study of Pregabalin in Patients With Chronic Neuropathic Pain. | |||
Brief Summary | Evaluate long-term safety and efficacy of pregabalin in patients with chronic neuropathic pain. | |||
Detailed Description | Not Provided | |||
Study Type ICMJE | Interventional | |||
Study Phase ICMJE | Phase 3 | |||
Study Design ICMJE | Allocation: Non-Randomized Intervention Model: Single Group Assignment Masking: None (Open Label) Primary Purpose: Treatment | |||
Condition ICMJE | Pain | |||
Intervention ICMJE | Drug: Pregabalin | |||
Study Arms ICMJE | Not Provided | |||
Publications * | Not Provided | |||
* Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline. | ||||
Recruitment Information | ||||
Recruitment Status ICMJE | Completed | |||
Enrollment ICMJE | 325 | |||
Original Enrollment ICMJE | Same as current | |||
Study Completion Date ICMJE | August 2005 | |||
Primary Completion Date | Not Provided | |||
Eligibility Criteria ICMJE | Inclusion Criteria:
Exclusion Criteria:
| |||
Sex/Gender ICMJE |
| |||
Ages ICMJE | 18 Years and older (Adult, Older Adult) | |||
Accepts Healthy Volunteers ICMJE | No | |||
Contacts ICMJE | Contact information is only displayed when the study is recruiting subjects | |||
Listed Location Countries ICMJE | Not Provided | |||
Removed Location Countries | ||||
Administrative Information | ||||
NCT Number ICMJE | NCT00141362 | |||
Other Study ID Numbers ICMJE | 1008-000-166 | |||
Has Data Monitoring Committee | Not Provided | |||
U.S. FDA-regulated Product | Not Provided | |||
IPD Sharing Statement ICMJE | Not Provided | |||
Responsible Party | Not Provided | |||
Study Sponsor ICMJE | Pfizer | |||
Collaborators ICMJE | Not Provided | |||
Investigators ICMJE |
| |||
PRS Account | Pfizer | |||
Verification Date | December 2006 | |||
ICMJE Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP |